AHP's Therapeutic Franchises: A Solid Foundation for Growth and Innovation AHP today has one of the strongest product portfolios of any company in the pharmaceutical industry. Anchored by breakthrough therapies and strengthened by innovative products from our R&D pipeline, AHP's pharmaceuticals, consumer health care products and animal health products provide a solid foundation for growth and innovation and support our continued expansion as a global health care leader. The following pages highlight the latest developments in our key therapeutic franchises and offer testimonials from some of the people whose quality of life is enhanced by AHP's products.

AHP has been a leader in women's health care for nearly 60 years. Our Women's Health Care franchise is anchored by the Premarin family, the most widely used hormone replacement therapy (HRT) for postmenopausal women. The Premarin family of products achieved nearly $1.9 billion in global sales this year, a 5 percent increase over 1999, led by sales of the combination HRT products - Prempro and Premphase -which grew 19 percent in 2000. The Premarin family of products was the most prescribed medication in the United States during 2000.

Efforts continued to expand this important product line in 2000, including the filing of regulatory submissions in the United States for lower dose formulations of Premarin and Premarin/MPA products for the relief of moderate to severe vasomotor symptoms associated with menopause. An additional indication for the prevention of osteoporosis is expected to be filed for regulatory approval during 2001.

A key area of HRT research focuses on therapies that incorporate trimegestone, a novel progestin licensed from Aventis Pharma and developed by Wyeth-Ayerst. In 2000, AHP received marketing approval in Sweden for the first trimegestone product on the market, Totelle -an HRT product containing trimegestone and 17 ß-estradiol for the prevention of osteoporosis and the relief of menopausal vasomotor symptoms. Totelle is undergoing regulatory review throughout the other European Union countries. Another new combination HRT, using Premarin and trimegestone, is undergoing Phase III clinical trials in the United States.

AHP also is conducting a major research program in tissue-selective estrogens, which target specific tissue systems and promise to provide clinicians and users with selective hormone treatments to optimize efficacy and tolerability. During 2001, Phase III clinical trials will begin for AHP's tissue-selective estrogen-TSE-424-for postmenopausal osteoporosis.

In addition to its menopausal health research programs, AHP is a global leader in hormone-based hormone-based oral contraceptive (OC) research and holds a leading market position worldwide. Recently, we received approval for a new gestodene-based OC, Minesse, in 17 countries. Minesse is the lowest dose oral contraceptive available on the international market. Submissions for regulatory approval in five additional countries were filed for Minesse in 2000. AHP's other major OCs include Alesse and Triphasil.

"I started taking Premarin about eight years ago. It's been a good choice for me because I haven't experienced the menopausal symptoms that I hear about from so many of my friends. I consider myself fortunate to be in such good health, and I definitely think Premarin is part of the reason." Diane Dunn-Columbus, Ohio- with daughters Katherine, Meghan and Barbara